Equinix's AI Toll Booth Story Remains a Show-Me Situation

What happened

Equinix's Q2 2026 results, released July 29, showed 16% revenue growth, 18-19% AFFO per share growth, record interconnection adds, and the largest guidance raise in company history, reinforcing its role as critical AI infrastructure. Management raised FY2026 revenue growth guidance to 11-12% and AFFO per share growth to 10-12%, with a long-term revenue growth target of 10-13% through 2029, reflecting strong demand from enterprises and hyperscalers. However, the stock already trades at elevated multiples (29.6x EV/EBITDA, 64.6x P/E) with negative free cash flow due to accelerating capex, leaving no margin of safety at current levels. The primary risk is execution: converting record bookings and $15 billion in RPO into recurring revenue while managing power constraints, permitting delays, and a stepped-up capital plan of $5-6 billion for 2026 and $5-7 billion annually for 2027-2029. The Seeking Alpha article reinforces the popular 'AI toll booth' narrative but introduces no new information beyond what was already considered in our WAIT rating; the next 3-6 months will be critical for evidence of clean revenue conversion and named AI deployments.

Implication

EQIX's interconnection moat and AI-driven demand are real, but the stock's premium valuation leaves little room for execution missteps. Key near-term catalysts include Q3 revenue within guidance without one-time benefits, sustained MRR growth above 11%, and proof that AI partnerships convert into named deployments. Risks include further capex escalation, equity issuance, or delays from power and permitting constraints, which could pressure AFFO and the stock. A more attractive entry point is around $920, with a trim level above $1,120; the current price near $1,008 is mid-range and not compelling. We would revisit the rating if management demonstrates stronger backlog-to-revenue conversion or if the stock pulls back to our entry zone, but for now we maintain WAIT.

Thesis delta

The thesis remains WAIT; the article's bullish framing largely echoes what is already priced in. No shift in conviction; attractive entry remains around $920, trim above $1,120, with re-assessment after Q3-Q4 results show backlog-to-MRR conversion and capex discipline.